Colin Booth leaves Glaxo SmithKline to become vice president science and technology at culture media and diagnostic microbiology specialist Oxoid
With 30 years experience in pharmaceutical microbiology - working for some of the world's leading pharmaceutical giants, such as ICI Pharmaceuticals (now Astra Zeneca), Glaxo, Glaxo Wellcome, and Glaxo SmithKline, Colin Booth has joined Oxoid as vice president science and technology and will be based at its Basingstoke headquarters.
Offering a valuable insight into one of Oxoid's expanding markets, the pharmaceutical industry, Colin has first-hand experience of the challenges faced by large, highly-regulated companies.
With this background, he will help Oxoid to achieve long term goals in terms of quality, delivery and innovation, focussing on customer needs throughout all industry sectors.
